Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Amvuttra now enters a potentially lucrative field largely dominated by Pfizer, whose Vyndaqel (tafamidis) family of transthyretin (TTR) stabilizer drugs won their initial ATTR-CM nods from the FDA ...

The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to compete with Pfizer’s Vyndamax and BridgeBio’s Attruby.

setting it up to compete with therapies from BridgeBio and Pfizer. Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Amvuttra is entering the ATTR cardiomyopathy market behind products from Pfizer that have become the standard of care and a BridgeBio Pharma drug approved last fall. But Amvuttra introduces a new ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Vutrisiran (Amvuttra), a small-interfering RNA (siRNA) therapy, is now the third drug approved by the US Food and Drug Administration for the treatment of adults with transthyretin amyloid ...

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...

The ATTR-CM market has grown more competitive following Food and Drug Administration approval of BridgeBio's Attruby in November 2024. There is also competition from Pfizer's Vyndaqel and Vyndamax ...

Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare ...

The ATTR-CM market is currently dominated by Pfizer’s Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s recently approved Attruby (acoramidis). Unlike these medications, which are TTR stabilisers ...